Suzman DL - Search Results

1

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.

Brave MH, Maguire WF, Weinstock C, Zhang H, Gao X, Li F, Yu J, Fu W, Zhao H, Pierce WF, Chang E, Dinin J, Fiero MH, Rahman NA, Tang S, Pazdur R, Kluetz PG, Amiri-Kordestani L, Suzman DL. Brave MH, et al. Among authors: suzman dl. Clin Cancer Res. 2024 Nov 1;30(21):4815-4821. doi: 10.1158/1078-0432.CCR-24-1393. Clin Cancer Res. 2024. PMID: 39230571 Clinical Trial.

2

Bone-targeting agents in prostate cancer.

Suzman DL, Boikos SA, Carducci MA. Suzman DL, et al. Cancer Metastasis Rev. 2014 Sep;33(2-3):619-28. doi: 10.1007/s10555-013-9480-2. Cancer Metastasis Rev. 2014. PMID: 24398856 Free PMC article. Review.

3

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Suzman DL, et al. Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844. Epub 2014 Jul 22. Prostate. 2014. PMID: 25053178 Free PMC article.

4

High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer.

Suzman DL, Antonarakis ES. Suzman DL, et al. Clin Genitourin Cancer. 2014 Apr;12(2):e51-3. doi: 10.1016/j.clgc.2013.11.015. Epub 2013 Nov 14. Clin Genitourin Cancer. 2014. PMID: 24332506 Free PMC article. No abstract available.

5

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.

Suzman DL, Antonarakis ES. Suzman DL, et al. Oncology (Williston Park). 2014 Oct;28(10):880, 882. Oncology (Williston Park). 2014. PMID: 25323614 Free article. No abstract available.

6

Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?

Suzman D, Eisenberger M. Suzman D, et al. Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. Epub 2014 Apr 13. Eur Urol. 2014. PMID: 24751214 No abstract available.

7

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer.

Suzman DL, Antonarakis ES. Suzman DL, et al. Cancers (Basel). 2015 Sep 29;7(4):1983-93. doi: 10.3390/cancers7040871. Cancers (Basel). 2015. PMID: 26426053 Free PMC article. Review.

8

Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.

Agrawal M, Kanakry J, Arnold CA, Suzman DL, Mathieu L, Kasamon YL, Gladstone DE, Ambinder RF, Ghosh N. Agrawal M, et al. Among authors: suzman dl. Ann Hematol. 2014 Jul;93(7):1245-6. doi: 10.1007/s00277-013-1950-7. Ann Hematol. 2014. PMID: 24232305 Free PMC article. No abstract available.

9

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.

Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R. Kazandjian D, et al. Among authors: suzman dl. Oncologist. 2016 May;21(5):634-42. doi: 10.1634/theoncologist.2015-0507. Epub 2016 Mar 16. Oncologist. 2016. PMID: 26984449 Free PMC article. Clinical Trial.

10

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.

Kazandjian D, Keegan P, Suzman DL, Pazdur R, Blumenthal GM. Kazandjian D, et al. Among authors: suzman dl. Semin Oncol. 2017 Feb;44(1):3-7. doi: 10.1053/j.seminoncol.2017.01.001. Epub 2017 Feb 10. Semin Oncol. 2017. PMID: 28395760 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters